HUTCHMED fanregratinib hits 42.5% ORR in pivotal ICC Phase II

HUTCHMED's FGFR2-targeted oral candidate met its primary endpoint in pretreated intrahepatic cholangiocarcinoma, supporting a China NMPA priority review NDA.

The Biotech Times Editorial Team By The Biotech Times Editorial Team
A brightly lit, modern medical imaging room features a white Samsung MRI machine with an attached patient table, a control console, and three wall-mounted monitors displaying vibrant medical scans.

HUTCHMED has reported pivotal Phase II data for fanregratinib (HMPL-453) in patients with advanced intrahepatic cholangiocarcinoma harbouring FGFR2 fusions or rearrangements, with the study meeting its primary endpoint and supporting an ongoing regulatory submission in China.

The single-arm, open-label trial enrolled patients across 53 sites in China, all of whom had received at least one prior line of systemic therapy. The Independent Review Committee-assessed objective response rate (ORR) reached 42.5% (95% CI: 30.0–53.6%), and the disease control rate came in at 83.9% (95% CI: 74.5–90.9%). Median time to response was 1.4 months, with a median duration of response of 6.9 months. Median progression-free survival was 6.9 months and median overall survival was 16.6 months.

The results will be presented at the ESMO Gastrointestinal Cancers Congress in Munich on 4 July 2026 by lead author Professor Jianming Xu of the Chinese PLA General Hospital, who served as the study's principal investigator.

Regulatory milestone

An NDA for fanregratinib in this indication was accepted and granted priority review by China's National Medical Products Administration (NMPA) in December 2025, making this data readout directly registration-enabling. All patients in the study had previously received chemotherapy and 72% had prior immunotherapy exposure, making the pretreated population notably challenging. Treatment discontinuation due to drug-related adverse events was limited to 2.2%, and no treatment-related deaths were recorded, though Grade 3 or higher drug-related adverse events occurred in 48.3% of patients, with liver enzyme elevations and palmar-plantar erythrodysesthesia the most commonly reported.

Professor Xu described the clinical setting as "highly challenging" and said the results "represent an important milestone in the targeted treatment landscape for FGFR2-altered ICC."

Competitive landscape

Fanregratinib enters a targeted therapy field in FGFR2-altered ICC that already includes approved selective FGFR inhibitors. Pemigatinib, developed by Incyte, received FDA approval in this indication in 2020, and infigratinib from QED Therapeutics followed. Futibatinib, a covalent FGFR inhibitor from Taiho Oncology, has also been approved by the FDA and EMA. All three are active in FGFR2 fusion-positive cholangiocarcinoma, meaning HUTCHMED will need to differentiate fanregratinib on efficacy, tolerability, or market access grounds, particularly in the Chinese market where domestic approval pathways and pricing dynamics differ materially from Western markets.

HUTCHMED retains worldwide rights to fanregratinib, giving it full commercial optionality. The company is already a commercial-stage organisation in China, with three medicines marketed domestically and one approved in the US, Europe, and Japan. Whether it pursues a global regulatory strategy for fanregratinib beyond the NMPA submission will be a key question for investors watching this programme. ICC with FGFR2 alterations represents a molecularly defined but relatively small patient subset, so the commercial opportunity, while real, is niche. A label in China would nonetheless represent meaningful validation of the platform and the company's ability to run registration-quality trials.

Topic

Geography